Having trouble accessing articles? Reset your cache.

Merck licenses NASH, diabetes compound from NGM

Merck & Co. Inc. (NYSE:MRK) exercised an option to license exclusive, worldwide rights to MK-3655

Read the full 156 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE